UNLOOC aims to develop groundbreaking Organ-on-Chips (OOC) technologies to mitigate the challenges posed by use of animals in drug development and testing. Direct use of human cells is a real game changer, bridging the gender gap and allowing personalized medicine.
UNLOOC is a 3-year project tackling the challenge inherent in animal testing of drugs. It brings together 51 organisations from 10 European countries. The consortium aims to demonstrate through its five novel use cases how the groundbreaking methods using Organ-on-a-Chip (OOC) technology enable the development of more effective treatments, leaving animal subjects out of the equation. The OOC technology to be developed in the UNLOOC project will not only enable controlled drug testing, but also the modelling of disease pathophysiology. The project’s total budget of €68 million consists of €14 million in funding from the Chips Joint Undertaking, €3 million from Swiss State Secretariat for Education, Research and Innovation (SERI), €18 million from national agencies and €33 million from partners’ own contribution.